At 13 years old, Perry is a courageous three-time rare cancer survivor. Now she's fighting back for others like her. JOIN THE BATTLE. http://www.cycleforsurvival.org.
Eagle Rare Kentucky Straight Bourbon Whiskey has named Angie Goodwin of Calhoun, Ky., as the winner of the Grand Prize 2014 Rare Life Award. Eagle Rare will donate $40,000 to Goodwin’s charity, Thumbs Up for Lane Goodwin Childhood Cancer Foundation, and host an awards ceremony in Henderson on March 7. Angie and her late son Lane started the foundation to support childhood cancer research through funding and advocacy and to assist families battling childhood cancer by providing education, financial assistance and a volunteer network.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64624-eagle-rare-bourbon-angie-goodwin-grand-prize-2014-rare-life-award
This year, Bob Evans Farms is partnering with JDRF for the second year, with a goal of raising $100,000 for T1D research by selling JDRF’s signature paper sneakers in each of its 561 restaurants.
Starting today through March 19, guests can support the fight against T1D by making donations of their choice to JDRF at their local Bob Evans restaurant. Guests interested in making a contribution will receive one of JDRF’s paper sneakers to sign and display. In addition, on March 19, Bob Evans will host a national community fundraiser, donating 15 percent of sales to JDRF when guests present a fundraising flyer. To access and download the community fundraiser flyer, visit Bob Evans’ Curing Diabetes Facebook page.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65919-bob-evans-farms-fight-against-type-1-diabetes-t1d-jdrf-partnership
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
The St. Jude Promesa y Esperanza® (Promise and Hope), an initiative by St. Jude Children’s Research Hospital® and Univision Radio, the leading radio network serving Hispanic America, partner to increase awareness for national fundraiser against childhood cancer. As part of this partnership, Univision Radio will broadcast special programming on February 10 and 11 asking listeners to become Angeles de Esperanza (Angels of Hope) by making a donation of $20 per month, to find cures and save children.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65476-univision-radio-st-jude-children-s-research-hospital-national-fundraiser
Weill Cornell Medical College today opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill Cornell’s existing research space and empowers scientists to rapidly translate groundbreaking discoveries into the most advanced patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65415-weill-cornell-medical-college-belfer-cancer-research-building-opening
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Back App proven to improve back pain and prevent office workers from falling victim to Sitting Disease, is a chair that is very different from all others.
Back pain is a modern epidemic, with recent high profile victims including UK Prime Minister David Cameron, model Jodie Kidd and tennis ace Andy Murray.
With 80% of people experiencing some form of back pain in their lifetime and the rise of tablet computers creating a generation hunched over screens - dubbed the ‘iPosture’ generation – the Back App is more relevant than ever in the effort to combat Sitting Disease which, in addition to back pain, has been linked to cardiovascular illness and cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/51361-back-app-guarantee-improved-back-pain
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
